KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $674.1 million.

  • Emergent BioSolutions' Non-Current Assets fell 17.43% to $674.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $674.1 million, marking a year-over-year decrease of 17.43%. This contributed to the annual value of $791.0 million for FY2024, which is 30.84% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Non-Current Assets stood at $674.1 million, which was down 3.37% from $697.6 million recorded in Q2 2025.
  • Emergent BioSolutions' Non-Current Assets' 5-year high stood at $2.0 billion during Q4 2022, with a 5-year trough of $674.1 million in Q3 2025.
  • Its 3-year average for Non-Current Assets is $1.0 billion, with a median of $859.0 million in 2024.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Assets increased by 15.88% in 2022, and later plummeted by 41.53% in 2023.
  • Emergent BioSolutions' Non-Current Assets (Quarterly) stood at $1.7 billion in 2021, then grew by 15.88% to $2.0 billion in 2022, then crashed by 41.53% to $1.1 billion in 2023, then slumped by 30.84% to $791.0 million in 2024, then fell by 17.43% to $674.1 million in 2025.
  • Its last three reported values are $674.1 million in Q3 2025, $697.6 million for Q2 2025, and $719.3 million during Q1 2025.